ReviewFrontiers in nutrition2025
Long-term/home parenteral nutrition: expert consensus statements regarding intravenous lipid emulsions.
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An International Expert Consensus Statement and Guidance Document on Implementation of Nutritional Supplementation in Patients on Dialysis.Kidney international reports · 2026Article
- Bridging the Gap in the Clinical Application of Advanced Parenteral Nutrition Formulations: From Efficacy to Real-World Challenges.Advances in nutrition (Bethesda, Md.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Home parenteral nutrition (HPN) is the primary life-saving therapy for patients with chronic intestinal failure (CIF). Patients requiring palliative nutrition, such as those with advanced cancer, may also benefit from HPN. Lipids are an integral part of parenteral nutrition (PN), but the use of intravenous lipid emulsions (ILEs) in PN continues to raise numerous questions for clinicians despite improved understanding and knowledge. The Lipids in PN Summit involved a panel of international experts with extensive research and clinical experience in use of PN. They assessed the current state of knowledge and developed expert consensus statements regarding the use of ILEs in patients requiring PN. The statements are also provided to help bridge the gaps between evidence and clinical practice, hence complementing formal societal guideline recommendations for the use of PN. This review briefly summarizes the rationale for considering ILE choice as a central component of any strategy for HPN patients, and discusses aspects of special interest within the context of HPN and long-term PN use in general such as essential fatty acid (EFA) delivery, the prevention of IF-associated liver disease (IFALD), and clinical evidence within HPN populations. In particular, potential clinical advantages of modern composite ILEs containing fish oil are reviewed, with biological effects of omega-3 polyunsaturated fatty acids (PUFAs) imparting additional clinical benefits. A future perspective section shares some proposals to address the difficulties of data generation within HPN, and suggested approaches to take as part of current clinical practice in the absence of definitive data. For now, the existing body of evidence should provide the basis for clinical care, and where evidence is lacking expert recommendations must suffice. The consensus statements from the Lipid Summit aim to summarize aspects mostly relevant for everyday clinical care; those relevant to the HPN setting are presented in this review.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.